-
Product Insights
Likelihood of Approval Analysis for Peripheral Neuropathy (Sensory Neuropathy)
Overview How likely is it that the drugs in Peripheral Neuropathy (Sensory Neuropathy) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peripheral Neuropathy (Sensory Neuropathy) Overview Peripheral neuropathy refers to a...
-
Thematic Analysis
NewNext-Generation Chips – Thematic Intelligence
Next-Generation Chips Thematic Report Overview Next-generation chips represent the next frontier of semiconductor technology, incorporating advancements in design, materials, manufacturing process, performance, and packaging. Next-generation chips are paramount to the digital transformation heralded by growth in AI tools. They are also required for the development of autonomous vehicles and quantum computing. The semiconductor industry faces several imminent challenges. These include a compounding skills shortage, rapidly growing energy demands, the escalating US-China trade war, and disconcerting concentrations of power in a...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) ·      Receptor Agonist ·      Enzyme Inhibitor ·      Biological Factor Activator ·      Ligand Inhibitor ·      ...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Systemic Lupus Erythematosus Drug Details: Mosunetuzumab (Lunsumio) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma Drug Details: Mosunetuzumab (Lunsumio) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Mantle Cell Lymphoma Drug Details: Mosunetuzumab (Lunsumio) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navepegritide in Achondroplasia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navepegritide in Achondroplasia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navepegritide in Achondroplasia Drug Details: Navepegritide (TransCon CNP) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:...